Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You still following LDS* Boston ?
It's great to see MGC come through with it's first delivery of Cannepil before year end!! 2018 has been a huge banner year for MGC with many milestones accomplished. We enter into 2019 with everything in place!! Congratulations to all Longs holding!!! See you in 2019!
MGC
MXC First CannEpilTM Product arrives in Australia
? In a significant milestone event for the Company, the first shipment of CannEpilTM was officially exported from Slovenia on Friday to arrive in Australia today, Monday 24 December
? All Australian import authorisations are in place to allow immediate transport to a secure facility at St Vincent’s Hospital, Melbourne
? CannEpilTM is available for supply through Authorised Prescribers, endorsed by the
Human Research Ethics Committee at St Vincent’s Hospital
? CannEpilTM is a Cannabinoids based IMP Phytomedicine developed by MXC
? Some Australian medical practitioners have already been granted approval as Authorised Prescribers of CannEpilTM
? MXC and specialist pharmaceutical distributor, HL Pharma, are now able to arrange the supply of CannEpilTM for patients who have been prescribed the product by an Authorised Prescriber
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce that its first investigational medicinal product (IMP) CannEpilTM has been successfully exported from Slovenia and imported into Australia today for the first time, after completing the validation process. The Company’s first batch of CannEpilTM will arrive in Australia today after being air freighted from Slovenia over the weekend.
MXC manufactures high quality products in accordance with European GMP standards. CannEpilTM is a Cannabinoids based IMP Phytomedicine developed by MXC.
MXC and HL Pharma will work together to arrange for the supply of CannEpilTM in Australia to eligible Authorised Prescribers.
Authorised Prescribers may prescribe CannEpilTM to suitable patients under their care.
Some of the Authorised Prescribers of CannEpilTM were first endorsed by the Human Research Ethics Committee at St Vincent’s Hospital, Melbourne.
1 - 2
The arrival of CannEpilTM into Australia for the first time represents a significant milestone for the Company and its development as an accomplished European-based biopharma company with more than a decade of clinical experience and a leading Board of scientific advisors.
Who is an Authorised Prescriber?
An Authorised Prescriber is a medical practitioner who has been authorised to prescribe a medicine which has not otherwise been approved for use in Australia by the Therapeutic Goods Administration (TGA). In order to obtain authorisation to be an Authorised Prescriber, a medical practitioner must obtain endorsement from an Ethics Committee, which requires the medical practitioner seeking to become an Authorised Prescriber to demonstrate the safety of the medicine and their expertise to prescribe it.
The Company continues to focus on research, development and production of further medicinal cannabis- based products to bring them to market in Australia and internationally.
Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented
“The arrival of CannEpil in Australia is a great achievement for us on our pathway to growing and commercialising MXC as a European-based biopharma company. The team has been working extremely hard to get to this stage and we are all very excited that CannEpil is now available for supply to patients in Australia, which is the first key market for the Company to deliver CannEpil into with more to follow during 2019.”
For further information, please contact:
Media Enquiries
Justin Kelly
Media and Capital Partners
+61 408 215 858 Justin.kelly@mcpartners.com.au
About MXC
MGC Pharmaceuticals Ltd
Brett Mitchell
Executive Chairman
+61 8 6382 3390 info@mgcpharma.com.au
--Ends—
MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based bio-pharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders are key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoid-based pharmaceutical products for the growing demand in the medical markets in Europe, North America and Australasia.
Follow us through our social media channels
2 - 2
• In a significant milestone event for the Company, the first shipment of CannEpil™was officially exported from Slovenia on Friday to arrive in Australia today, Monday24 December
• All Australian import authorisations are in place to allow immediate transport to asecure facility at St Vincent’s Hospital, Melbourne
• CannEpilTM is available for supply through Authorised Prescribers, endorsed by theHuman Research Ethics Committee at St Vincent’s Hospital
• CannEpilTM is a Cannabinoids based IMP Phytomedicine developed by MXC
• Some Australian medical practitioners have already been granted approval asAuthorised Prescribers of CannEpilTM
• MXC and specialist pharmaceutical distributor, HL Pharma, are now able to arrangethe supply of CannEpilTM for patients who have been prescribed the product by anAuthorised Prescriber
There is a video available on Facebook - I don’t know how to post a link, but if you go to Facebook and search “Lorne Gertner kicking off Cannatech Hong Kong” you should find it. There are two speakers before Gertner. He talks about Cannaglobal among other things.
Agreement signed with renowned research universities
19 November 2018 ASX Code: MXC
?
? ?
?
?
?
?
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce it has signed a binding partnership agreement with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to form a joint international medical research hub for medicinal cannabis innovation and technologies.
As an extension to MXC existing collaboration with RMIT, the new research hub, to be known as ‘CannaHub’, is a collaborative centre between MXC, RMIT and HUJ and will be an international shared library of research, data and analytics on medicinal cannabis and its uses including future medical applications and treatments.
to launch CannaHub
An international research hub formed for the development of world leading medicinal
cannabis research, technologies and innovations
Highlights
MXC has signed a partnership agreement with the Royal Melbourne Institute of Technology (RMIT) and The Hebrew University of Jerusalem (HUJ) to create and launch ‘CannaHub’, an international research hub for medicinal cannabis and its
future applications in the field of medicine and patient treatment
CannaHub is a new addition to the MXC projects currently underway with RMIT,
and will be formally launched in Q1 2019
CannaHub’s research projects will initially focus on the use of medicinal cannabis in the treatment of cancer, the effectiveness of traditional and medicinal cannabis
combination treatments and drug delivery systems
Partnering with world renowned Hebrew University of Jerusalem in a research
collaboration project further strengthens the Company’s business strategy to
become a leading bio-pharma, and product development company
Represents a key milestone for the Company as CannaHub will act as MXC’s primary research and new product development engine, supporting its seed-to- pharma business model through the innovation and development of new
medicinal cannabis products and technologies
All findings, outcomes and conclusions remain the property of CannaHub partners
MXC, RMIT and HUJ
MXC holds the first right to use or acquire all data, technology, or findings
generated from CannaHub with potential commercial applications
So there is a lot not happening with MGC right now. Anybody have any thoughts?
With the American penny pot stocks heating up (KGKG VATE SIPC etc.) there doesn't seem to be any reason to hold MGCLF. So I got out. Good luck to all longs!
Market Announcement 1 November 2018
MGC Pharmaceuticals Ltd (ASX: MXC) – Trading Halt
Description
The securities of MGC Pharmaceuticals Ltd (‘MXC’) will be placed in trading halt at the request of MXC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 5 November 2018 or when the announcement is released to the market.
Issued by
Sandra Wutete
Senior Adviser, Listings Compliance (Perth)
https://hotcopper.com.au/documentdownload?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD4wi7wBaZre96ke92GA%3D%3D
MXC partner with Epilepsy Action Australia to launch medical
30 October 2018 ASX Code: MXC
cannabis education platform
? MXC collaborates with Epilepsy Action Australia to design and build an online education platform for medicinal cannabis and epilepsy
? The Platform will be designed for the everyday use of healthcare professionals and epilepsy patients, as a gateway to knowledge on epilepsy and access to medical cannabis treatments
? Showcases MXC’s commitment to providing education and improving the lives of epilepsy sufferers
? MXC committed to finance phase one of the project with Epilepsy Action Australia
? Phase one of the project will be presented at the CannaTech conferences, hosted in
Sydney between 28th – 30th October
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce it has partnered with Epilepsy Action Australia (EAA) to create an online platform dedicated to providing information and education on medicinal cannabis and epilepsy.
The platform will take the form of an EAA website and is designed as an effective online educational tool that provides easily packaged, accessible, user-friendly information about epilepsy and medicinal cannabis.
The platform is intended for healthcare practitioners and patients suffering from epilepsy and will provide information via its ‘Get Educated” and ‘Get Access’ portals. These portals will consist of news, research breakthroughs and information on how to access medicinal cannabis treatments and clinical trials.
The website will be populated by epilepsy and pharmaceutical experts and phase one of the project will be presented at the CannaTech conference on the 28th – 30th October in Sydney.
The Company has committed to finance phase one of the EAA project and design and development has already commenced.
1 - 2
Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented
“I am delighted to announce we have everything in place to begin the design and development of our education project in collaboration with Epilepsy Action Australia. We are dedicated to improving the lives of epilepsy sufferers and will continue to research, develop and progress the clinical epilepsy market.”
Carol Ireland, CEO and Managing Director of Epilepsy Action Australia commented
“Epilepsy patients are always looking for reliable and trusted information and new research and we have noticed an influx of patients seeking information on medical cannabis. Partnering with MGC Pharma and launching the platform will allow us to provide patients with a portal to access all the information they need to help them better understand what options and alternatives are available to them.”
For further information, please contact:
Media Enquiries
Rosa Smith
Media and Capital Partners
+61 457 305 047 Rosa.smith@mcpartners.com.au
About MXC
MGC Pharmaceuticals Ltd
Brett Mitchell
Executive Chairman
+61 8 6382 3390 info@mgcpharma.com.au
--Ends—
MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.
Follow us through our social media channels
2 - 2
insert-text-here
Fantastic article!! Very detailed regarding our MGC. There is a ton of potential here and Mgt is executing very well on initiatives that were put in place the last few years. Pps is at a great entry point and also perfect for accumulation for Longs. The time to much greater awareness is coming fast!!
MGC
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) has today published its
Appendix 4C for the three-months ended 30 September 2018 and provides an overview
of its operational highlights for the period.
Operational Update
The Company achieved a number of significant milestones during the quarter on its path
towards becoming a world-leading pure Bio-Pharma company and demonstrating its full
seed-to-pharma capabilities.
Looks like a couple people need beer money for the weekend this morning. Staring at my calendar, realizing that including today, we are 9 business days away from the announcement.
Thank you for the update. October 31st is just around the corner! Plenty of time for people to load up!
An announcement from MGC tonight said the date had been moved back and everything will be finalized October 31 with CannaGlobal. CannaTech is in Sydney October 28-30 with some big names in the Cannabis industry. Lorne Gertner is one of the speakers. The timing makes sense knowing that.
Cannaglobalco.com
What's the website?
MGCLF
I’m suppose we’ll all be checking it multiple times daily now, lol
Hmmmm......... I see Cannaglobal has finally got what resembles a website up. Unfortunately not much to see or interact with yet. You can sign up for company news though, I’m sure in the coming days it will be well expanded.
624,223 volume today is much higher than most days. Maybe somebody knows something?
Trading halt may be due to the 1 mil Cannaglobal payment, but I have a feeling it may be more than that. Maybe news getting over to the US, or maybe another aspect of the Cannaglobal deal, or perhaps uplisting off the pinks. IDK, something is a brewing my MGCLF brothers and sisters!! We should know tomorrow night.
MGC
I agree with you that Australia is no doubt really big news. I feel it’s only the tip of the iceberg though. Much going on below the surface and behind the scenes that we’re not even privy to yet. It’s getting very interesting to say the least.
Still think the really big news is getting the epilepsy drug approved in Australia. Another GW Pharma in the making?
Couple the news of the UK legalizing MM come November 1st (which will be far less restrictive than Australia) and the company’s previous news release of striking a distribution deal with A.M. Mangion (look em up) and it’s easy to read the writing on the wall.
IMHO MGCLF is sitting steadily on the launching pad and the countdown has begun.
Ok, for those who haven’t figured it out on their own. The trading “pause” yesterday was implemented by the ASX in order for them to inquire MGC as to a reason for the sudden increase in sp and volume on MXC yesterday. MGC has gotten back to them in a very timely manner and with good explanation. MXC, after the pause in trading, initiated a trading halt at their own request pending a new announcement.
“ the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 18 October 2018 or when the announcement is released to the market.”
Based on the action on the ASX yesterday, I would venture to guess the news is very, very good, and probably contains more than just an announcement that the 1 mil from Cannaglobal has been received and is now on our books. A 5 year supply agreement with Cannaglobal is bigger than I think people realize.
The announcement is a trading halt. I’m sure it has something to do with the 1 mil from Cannaglobal, maybe more..........
Market Release Oct 16, 2018
MGC PHARMACEUTICALS LTD
Security Code: MXC
Pause in Trading
Trading in the securities of the entity will be temporarily paused pending a further announcement.
Isabelle Andrews
ASX Listings Compliance
Oct 16, 2018 Market Announcement 1/1
New announcement coming any moment. Trading paused on the ASX right now.
Exciting to watch the action in Australia tonight. Sittin pretty at 8 cents right now.
Typical pink sheet move. US investors know very little about this ticker at the moment. That will change very soon IMO which should help support the MGCLF ticker.
MGC
GonzoinHD...congrats!!! PM your cell#, if you want, and I'll text you my #. Welcome aboard!
MGCLF
MXC gets approval for its epilepsy drug in Aussie land and MXC goes down in the U.S.???
You have a very good handle on things. That's easy to see. It's going to start getting crazy around here and I could use the help once many more folks start showing up on this board. This party hasn't even started and I would be grateful if you partnered up to spread the good word!!
MGCLF
Sure, I’ll look into submitting a request to do so over the weekend. I imagine it would be fun. I’m flattered by the way rushman, thank you.
Hey Boston, are you still following LDS*?
MGC is now in the fast lane. The days of this ticker being a ghost in the US will end soon IMO and folks are going to start waking up to what we have here!! Very LONG this stock with what they have going on. The current pps is laughable as US investors are dimly aware. GW 2.0!!
MGCLF
Lock up your shares folks (limit sell order at very high price- good till cancelled)
I have a feeling the next couple weeks are going to be fun
$MGCLF$
Time for you to be a moderator...
MGCLF
3000 patients at 1million per 100 patients is 30 mil dollars in revenue!!!! Go MGC
Why isn’t my E*TRADE reflecting the gains they are having in Australia???
Why MGC Pharmaceuticals Ltd (ASX:MXC) shares have rocketed 27% higher today
James Mickleboro
James Mickleboro
Motley Fool 11October,2018, 12:25 am GMT
bull market investing
bull market investing
The market may have sunk lower on Thursday, but that hasn’t stopped the MGC Pharmaceuticals Ltd (ASX: MXC) share price from rocketing higher.
In morning trade the cannabis company’s shares are up 27.5% to 6.5 cents.
Why are MGC Pharmaceuticals’ shares rocketing higher?
This morning the company’s shares returned from a trading halt after announcing the receipt of formal authorisation for the availability of its product CannEpil for supply in Australia through specialist prescribers under the Authorised Prescriber Scheme.
CannEpil is CBD-based medication that is used as a treatment for people with refractory epilepsy.
Management believes that this formal authorisation is a major milestone representing the company’s progress towards becoming a world-leading bio-pharma company.
It also signals the start of commercial-scale production of CannEpil at its GMP certified facility in Slovenia and puts the company on the verge of revenue generation from its core pharma activity.
The first batch of the CannEpil product is expected to be available for sale in Australia by December and will be distributed by specialist Australian pharmaceutical distributor, HL Pharma.
It isn’t just the company that is pleased with this development. The chief executive officer of Epilepsy Action Australia, Carol Ireland, is equally pleased.
She stated that: “This is a significant milestone for epilepsy patients and other patient communities. It is another important step in improving access to potentially life-changing medications, and part of a global trend to recognize the valid medical benefits of cannabis.”
Should you invest?
This is undoubtedly a big positive for the company. Especially given its recent appointment of Assoc. Professor Wendyl D’Souza to the MGC Pharmaceuticals Medical Advisory board.
Mr D’Souza is an authorised prescriber of medicinal cannabis and has over 3,000 registered patients with drug resistant epilepsy from currently available anti-epilepsy medications.
If CannEpil can be successfully used to treat these patients then it could lead to solid sales growth and give it the edge over industry peers Althea Group (ASX: AGH), AusCann Group Holdings Ltd (ASX: AC8), and Cann Group Ltd (ASX: CAN).
However, it is early days and there are no guarantees that CannEpil will be a success. Because of this, I would suggest investors sit tight and wait to see how things progress over the next 12 months.
Well said and you brought up very good points. My husband has been saying for months Pharma is the place to be. Also, I had completely forgotten about our new Canadian connections. They are huge in the whole Cannabis industry. MGC will start to get more exposure. We are lucky investors to be holding now.
GLTA - It’s coming!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1011
|
Created
|
11/02/17
|
Type
|
Free
|
Moderators |
Our three pioneering divisions allow MGC to be a key player in all significant levels of production in various global locations. It also allows MGC to progress with simultaneous high level research and development, clinical trials around the world and to embrace new emerging verticals in CBD markets.
Founded in 2014 by experts in the Medical Cannabis field with the intention of capitalising on the emerging global Medical Cannabis industry, founders Nativ Segev and Roby Zomer bring a combination of over 10 years in the Medical Cannabis and the BioTech industry. MGC Pharma was created to become a leading BioPharma company based on Medical Cannabis with operations spanning all aspects of the value chain, from cultivation, manufacturing and distribution of products in a global market.
Today, MGC Pharma has operations spanning Europe and Australia. It has cultivated and harvested crops in its growing facilities in the Czech Republic and Slovenia and is manufacturing active pharmaceutical ingredients (APIs) at its European GMP extraction facility. The Company has also developed a CBD cosmetics range that is available for purchase throughout Europe and online via the Company’s eShop www.mgcderma.com
The Botanic Division engages with multiple cultivation sites to meet increasing global demand, alongside research into breeding and genetics with leading institutions and academia. We will continue to harvest the product in Slovenia and Czech Republic, and use the raw material at our production facility, as well as provide the product globally.
Our research & development:
The Innovation Division is focused on our medical product pipeline and is our largest division. This division focuses on products that emerge from our supply line. These include neutraceuticals, which will be able to provide the additional needs and requirements that our body demands on a daily basis to improve our immune system, detoxify and enhance wellness.
Additionally, this includes our extracts, at various levels of purity, and with the ability to extract various phytocannabinoids and terpenes to the level of Active Pharmaceutical Ingredient.
The Innovation division is focused on three specific areas of treatment:
MGC Derma produces CBD enhanced cosmetics, DermaPlus dermatological line and private label manufacturing.
Our research & development:
MGC Derma is the brand leading the way in utilising this year’s ‘it’ skin care ingredient: cannabis. Before you get the wrong end of the stick… we’re talking about cannabidiol (CBD) a totally non-psychoactive compound derived from the cannabis plant, which shares part of the ‘fingerprint’ of our genetics, allowing the body to instantly recognise it – and utilise it accordingly. It is MGC Derma’s unique, meticulous extraction and purification process that keeps this ‘fingerprint’ intact; the brand uses only the highest quality cannabidiol in this range of pure yet potent serums, masks, toners and cream. Renowned for its healing, sebum-regulating and moisturising capabilities, CBD is particularly adept at addressing eczema, acne and other problematic skin conditions, as well as minimising signs of ageing, hydrating and nourishing.
MGC Derma is the brand leading the way in utilising this year’s ‘it’ skin care ingredient: cannabis. Before you get the wrong end of the stick… we’re talking about cannabidiol (CBD) a totally non-psychoactive compound derived from the cannabis plant, which shares part of the ‘fingerprint’ of our genetics, allowing the body to instantly recognise it – and utilise it accordingly. It is MGC Derma’s unique, meticulous extraction and purification process that keeps this ‘fingerprint’ intact; the brand uses only the highest quality cannabidiol in this range of pure yet potent serums, masks, toners and cream. Renowned for its healing, sebum-regulating and moisturising capabilities, CBD is particularly adept at addressing eczema, acne and other problematic skin conditions, as well as minimising signs of ageing, hydrating and nourishing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |